Paper41002441
Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies.
Zoroddu S and 1 other. Cells, 2025. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies. Papers, record 41002441. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41002441
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Melanoma | Major topic |
| Cancer Vaccines | Major topic |
| mRNA Vaccines | Major topic |
| RNA, Messenger | Major topic |
| Humans | |
| Immunotherapy | |
| Animals |
Source PubMed
References84
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38282471 | Recent progress in mRNA cancer vaccines. | Hum Vaccin Immunother | 2024 | https://conductscience.org/library/papers/38282471 | PubMed |
| 2 | 41002395 | mRNA Multipeptide-HLA Class II Immunotherapy for Melanoma. | Cells | 2025 | https://conductscience.org/library/papers/41002395 | PubMed |
| 3 | 39827147 | Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges. | Mol Cancer | 2025 | https://conductscience.org/library/papers/39827147 | PubMed |
| 4 | 37339211 | Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination. | Proc Natl Acad Sci U S A | 2023 | https://conductscience.org/library/papers/37339211 | PubMed |
| 5 | 37414361 | mRNA: A promising platform for cancer immunotherapy. | Adv Drug Deliv Rev | 2023 | https://conductscience.org/library/papers/37414361 | PubMed |
| 6 | 39256822 | Current landscape of mRNA technologies and delivery systems for new modality therapeutics. | J Biomed Sci | 2024 | https://conductscience.org/library/papers/39256822 | PubMed |
| 7 | 40456769 | Multi-omics and AI-driven immune subtyping to optimize neoantigen-based vaccines for colorectal cancer. | Sci Rep | 2025 | https://conductscience.org/library/papers/40456769 | PubMed |
| 8 | 39290693 | Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity. | Front Immunol | 2024 | https://conductscience.org/library/papers/39290693 | PubMed |
| 9 | 29664013 | β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas. | J Clin Invest | 2018 | https://conductscience.org/library/papers/29664013 | PubMed |
| 10 | 38086815 | Therapeutic cancer vaccines: advancements, challenges, and prospects. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/38086815 | PubMed |
| 11 | 38890171 | Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study. | Virchows Arch | 2024 | https://conductscience.org/library/papers/38890171 | PubMed |
| 12 | 38238340 | Neoantigen vaccine nanoformulations based on Chemically synthesized minimal mRNA (CmRNA): small molecules, big impact. | NPJ Vaccines | 2024 | https://conductscience.org/library/papers/38238340 | PubMed |
| 13 | 39798545 | Clinical advances of mRNA vaccines for cancer immunotherapy. | Med | 2025 | https://conductscience.org/library/papers/39798545 | PubMed |
| 14 | 38239240 | Advanced nano-based strategies for mRNA tumor vaccine. | Acta Pharm Sin B | 2024 | https://conductscience.org/library/papers/38239240 | PubMed |
| 15 | 39590584 | Advances in mRNA LNP-Based Cancer Vaccines: Mechanisms, Formulation Aspects, Challenges, and Future Directions. | J Pers Med | 2024 | https://conductscience.org/library/papers/39590584 | PubMed |
| 16 | 30388456 | Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. | Cell | 2018 | https://conductscience.org/library/papers/30388456 | PubMed |
| 17 | 38582088 | Unlocking the power of nanomedicine: Cell membrane-derived biomimetic cancer nanovaccines for cancer treatment. | Med | 2024 | https://conductscience.org/library/papers/38582088 | PubMed |
| 18 | 37744371 | Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities. | Front Immunol | 2023 | https://conductscience.org/library/papers/37744371 | PubMed |
| 19 | 38242890 | Development and use of machine learning algorithms in vaccine target selection. | NPJ Vaccines | 2024 | https://conductscience.org/library/papers/38242890 | PubMed |
| 20 | 37511023 | RNAseq Analysis of Novel 1,3,4-Oxadiazole Chalcogen Analogues Reveals Anti-Tubulin Properties on Cancer Cell Lines. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37511023 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42898919 | miRNAs bridging the gap between the tumor microenvironment and liquid biopsy in cutaneous melanoma. | Front Immunol | 2026 | https://conductscience.org/library/papers/42898919 | PubMed |
| 42794593 | Personalized mRNA Neoantigen Vaccines in Cancer: Linking Precision Antigen Selection, Immune Remodeling, and Checkpoint Blockade. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794593 | PubMed |
| 42724148 | Therapeutic melanoma vaccines: Platforms, neoantigen strategies, and emerging combination immunotherapies. | Ther Adv Vaccines Immunother | 2026 | https://conductscience.org/library/papers/42724148 | PubMed |
| 42651807 | Engineering the Future of Precision Medicine: A Comprehensive Guide to RNA Therapeutics. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42651807 | PubMed |
| 42646699 | Advances in Therapeutic Melanoma Vaccines (2010-2025). | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42646699 | PubMed |
| 42614300 | From pathogen defence to precision health infrastructure: mRNA vaccines beyond infectious disease in preventive health, chronic disease management, and population wellbeing. | Front Bioeng Biotechnol | 2026 | https://conductscience.org/library/papers/42614300 | PubMed |
| 42565117 | Beyond the genetic code: orchestrating epigenetic and immune landscapes with multivalent mRNA-exosome vaccines. | Precis Clin Med | 2026 | https://conductscience.org/library/papers/42565117 | PubMed |
| 42482783 | mRNA cancer vaccines: delivery strategies, immune modulation, and clinical translation. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42482783 | PubMed |
| 42350438 | Next-generation mRNA vaccines: strategies to overcome stability challenges. | NPJ Vaccines | 2026 | https://conductscience.org/library/papers/42350438 | PubMed |
| 42344914 | From Jenner to genomics: the unfolding future of vaccinology. | Front Immunol | 2026 | https://conductscience.org/library/papers/42344914 | PubMed |
| 42162504 | Integrating multi-omics data for next-generation cancer research and precision medicine. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42162504 | PubMed |
| 41934551 | mRNA-based melanoma vaccines targeting gp100 and TRP2 macromolecules. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41934551 | PubMed |
| 41834982 | [Clinical Progress and Prospects of mRNA Tumor Drugs]. | Sichuan Da Xue Xue Bao Yi Xue Ban | 2026 | https://conductscience.org/library/papers/41834982 | PubMed |
| 41800027 | Tumor Cells as Architects of Immune Refractoriness: Dismantling Intrinsic Programs of Tumor Cells for Clinical Translation. | Immune Netw | 2026 | https://conductscience.org/library/papers/41800027 | PubMed |
| 41677661 | mRNA Vaccines in Melanoma Immunotherapy-A Narrative Review. | Cells | 2026 | https://conductscience.org/library/papers/41677661 | PubMed |
| 41597174 | Advances in mRNA-Based Melanoma Vaccines: A Narrative Review of Lipid Nanoparticle and Dendritic Cell Delivery Platforms. | Cells | 2026 | https://conductscience.org/library/papers/41597174 | PubMed |
| 41302945 | Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF-MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib. | J Clin Med | 2025 | https://conductscience.org/library/papers/41302945 | PubMed |
Genes18
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41002441
GET https://conductscience.org/api/papers/v1/41002441/references?page=2